GlassScriptPhysician profile
Thomas S Jung
NPI 1285875484
$13,463.78
in general payments reported to CMS, 2019-2025
39 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $1,007 · 2021: $2,003 · 2022: $2,463 · 2023: $2,138 · 2024: $2,324 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,174 · Education: $59.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,173.62 |
| Education | $59.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,899.76 | 2019-2025 | |
| Gilead Sciences, INC. | $1,790.65 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,486.97 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $1,052.25 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $798.92 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $771.94 | 2022-2025 | Ibsrela |
| Celgene Corporation | $695.65 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $454.28 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $423.21 | 2024-2025 | Voquezna |
| Pfizer INC. | $399.68 | 2019-2025 | |
| Qol Medical, LLC | $341.36 | 2021-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $244.01 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Intercept Pharmaceuticals, INC. | $197.94 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $180.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $179.11 | 2024-2025 | Omvoh |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.